Soft-tissue sarcomas are estimated to represent approximately 1% of all malignant tumors, and liposarcoma is the most common of the soft-tissue sarcomas. The median age range of patients ranges from 40 to 60 years, with males more commonly affected than females. Treatment is often multidisciplinary, with wide surgical resection and adjuvant radiation therapy as the mainstays of treatment. The use of chemotherapy for liposarcoma depends on tumor size, grade, histologic type, and the presence of metastases. A tumor size exceeding 5 cm, local invasion, metastases, and positive surgical margins have been shown to be negative prognostic factors in patients with liposarcoma.

This content is only available to members of the AAOS.

Please log in using the link at the top right corner of this page to access your exclusive AAOS member content.

Not a member? Become a member!